Magic Bullet
Wednesday, January 31st, 2007Last summer I wrote about Acomplia (rimonabant), the weight-loss pill that is also supposed to help smokers kick the habit.
I’ve eagerly awaited the availability of Acomplia in the U.S. since I first read about it several years ago. Alas, even though the drug is approved in the EU, our FDA has delayed approval here for more than a year. The agency did not approve Acomplia as a smoking cessation aid–they went so far as to make that call.
April 26
Finally, the FDA has set the date–their decision on Acomplia should be announced April 26. I take this as a very good sign–because April 26 is Jeff’s birthday. Not that I’m superstitious.
Some studies also have shown that Acomplia reduces blood sugar levels, improves cholesterol levels and reduces that most hazardous weight–the spare tire. And…smokers were twice as successful at quitting, with less weight gained in the process, than smokers who received a placebo.
Acomplia works differently than other drugs used as tobacco cessation aids. It blocks activation of cannabinoid receptors that stimulate your appetite for food–and nicotine. (Does the word cannabinoid sound familiar? It’s your body’s natural version of cannabis, the substance in marijuana that gives people the munchies.)
Acomplia also…
may just help people ditch other addictions, such as drug and alcohol dependencies. Acomplia is so promising that NIDA, the U.S. Institute of Drug Abuse is teaming up with Federsed, the Italian Federation Services for Drugs and Other Addictions to establish protocols for clinical studies of Acomplia as tool to fight other addictions.
Side Effects
Acomplia was tolerated fairly well in most of the studies completed thus far. The most common side effects have been transient dizziness and nausea. A small number of people have experienced depression and anxiety when taking the drug.
I’ve been around the block enough times to know the bulk of the work of quitting smoking and losing weight is personal effort. But a little help sure doesn’t hurt.

